About MaxiVAX

The first company with an encapsulated cellular cancer immunotherapy

MaxiVAX is a Swiss clinical-stage biotechnology company which, having completed a first-in-man Phase I clinical study, is now planning to perform several Phase II multicenter studies in different types of cancer.

Learn more

Cancer Immunotherapy

A paradigm-shift in cancer treatment

First generation cancer immunotherapies are paving the way for MaxiVAX’s personalized immunotherapy.

Learn more



A novel and proprietary way to reprogram and boost the patient’s own immune system for fighting cancer.

Learn more


Highly experienced product development team

A very seasoned team with extensive experience in the fields of clinical oncology, cell therapy, quality assurance, clinical research and regulatory affairs.

Learn more

Phase I clinical trial completed

See the detailed Press Release.

Contact info

Do you need more information? Feel free to contact us

Rue de l'Athénée 24
1206 Geneva

+41 22 552 26 13